GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Kindstar Globalgene Technology Inc (HKSE:09960) » Definitions » Stock Based Compensation

Kindstar Globalgene Technology (HKSE:09960) Stock Based Compensation : HK$0 Mil (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Kindstar Globalgene Technology Stock Based Compensation?

Kindstar Globalgene Technology's Stock Based Compensation for the six months ended in Jun. 2023 was HK$0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 was HK$0 Mil.


Kindstar Globalgene Technology Stock Based Compensation Historical Data

The historical data trend for Kindstar Globalgene Technology's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindstar Globalgene Technology Stock Based Compensation Chart

Kindstar Globalgene Technology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial - - - - -

Kindstar Globalgene Technology Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kindstar Globalgene Technology Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.


Kindstar Globalgene Technology Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Kindstar Globalgene Technology's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Kindstar Globalgene Technology (HKSE:09960) Business Description

Traded in Other Exchanges
N/A
Address
Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN
Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services. It organizes the business into nine segments, including hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, and Other segment provides Testing services for R&D projects and others and miscellaneous services.

Kindstar Globalgene Technology (HKSE:09960) Headlines

No Headlines